Harvest One launches Satipharm reformulated CBD capsules in Europe
Harvest One Cannabis Inc. reports the company’s wholly owned medical subsidiary, Satipharm Ltd., has launched European sales of its recently reformulated CBD capsules.
“The first product to market is the Satipharm 10 mg CBD Gelpell® capsule that provides superior bioavailability and quality,” notes a press release from Harvest One, a global cannabis company that develops and provides lifestyle and wellness products to consumers and patients in regulated markets around the world. They are currently available online at www.satipharm.com.
Bricks and mortar distribution of the capsules “will follow with major retailers throughout the United Kingdom and European Union, with Canadian distribution to follow,” the company statement reports.
Satipharm points out that its technology “improves the body’s absorption of CBD and other cannabinoids through a patented formulation of CBD hemp extract contained in seamless Gelpell® gelatine biospheres.” The biospheres “are placed in gastro-resistant capsules, ensuring the timely release of CBD in the small intestine, thereby improving bioavailability, and further ensuring patients receive a consistent dose of CBD,” it adds.
“We are delighted with the launch of Satipharm’s new website and e-commerce platform,” making the capsules available to consumers across Europe, comments company president Jonathan Hartshorn.
“The launch of Satipharm’s patented CBD Gelpell® formulated capsules is an integral part of Harvest One’s health and wellness strategy,” adds Grant Froese, CEO of Harvest One. “We look forward to the launch of additional product lines as we advance our health and wellness strategy in regulated markets around the world,” Foese says.
Source: 420 Intel – Europe